Carnival Corp vs Novo Nordisk A/S — how do they compare? Carnival Corp trades at $28 (market cap $37.98B), while Novo Nordisk A/S trades at $45.85 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.5× Carnival Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CCL | NVO | |
|---|---|---|
Market Cap | $37.98B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $63.98 |
52-Week Low | $23.89 | $35.29 |
Enterprise Value | $61.91B | $222.55B |
Dividend Yield | 1.62% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.75, down 4.28% today, amid a bearish technical signal. The company shows strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, net income turning positive to $2.76B, and positive cash flow of $727M in 2025. Recent earnings beats and a 59.57% analyst buy rating support optimism, though technical indicators show near-term pressure with support at $27.
Outlook remains positive driven by record travel demand, fleet expansion, and debt reduction, with a consensus price target of $35.18 offering 27% upside. Key risks include fuel price volatility, economic sensitivity, and execution of growth plans amid competitive pressures.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Trailing returns across standard periods
Latest headlines on both assets
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →